Mitochondrial tRNA processing defects reprogram mitochondrial and cellular homeostasis
Journal of Biological Chemistry · 2025
DOI: 10.1016/j.jbc.2025.110334 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025. Verfasst von Gao Zhu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Mitochondrial Biomedicine and Department of Otolaryngology-Head and Neck Surgery, The Fourth Affiliated Hospital, Zhejiang University Scho…. Hauptthemen laut MEDLINE: Mitochondria, Homeostasis, RNA, Transfer, RNA Processing, Post-Transcriptional. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Key Technologies Research and Development Program, National Key Research and Development Program of China.
Abstract (Originalsprache)
Mitochondrial tRNA processing defects have been associated with some clinical presentations including deafness. Especially, a deafness-linked m.7516delA mutation impaired the 5' end processing of RNA precursors and mitochondrial translation. In this study, we investigated the mechanism by m.7516delA mutation-induced deficiencies mitigate organellar and cellular integrity. The m.7516delA mutation downregulated the expression of nucleus-encoding subunits and upregulated assembly factors of complex IV and altered the assembly and activities of oxidative phosphorylation (OXPHOS) complexes. The impairment of OXPHOS alleviated mitochondrial quality control processes, including the imbalanced mitochondrial dynamics via increasing fission with abnormal mitochondrial morphology. The m.7516delA mutation upregulated both ubiquitin-dependent and independent mitophagy pathways, evidenced by increasing levels of Parkin, BNIP3, NIX, and MFN2-ubiquitination and altering interaction between MFN2 and MUL1 or Parkin, to facilitate the degradation of severely damaged mitochondria. Strikingly, the m.7516delA mutation activated the integrated stress response (ISR) pathway, evidenced by upregulation of GCN2, P-GCN2, p-eIF2α, CHOP, ATF4, and elevated the nuclear location of ATF5 to minimize the damages in defective mitochondria. Both activation of the ISR and PINK1/Parkin mitophagy pathways ameliorate the cell homeostasis via elevating the autophagy process and upregulating apoptotic pathways. Our findings provide new insights into underlying aberrant RNA processing-induced dysfunctions, reprogrammed organelles, and cellular integrity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Mitochondrial Biomedicine and Department of Otolaryngology-Head and Neck Surgery, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, Zhejiang, China; Institute of Genetics, Zhejiang…
- Institute of Genetics, Zhejiang University International School of Medicine, Hangzhou, Zhejiang, China.
- Department of Otolaryngology Head and Neck Surgery & Audiology and Neurotology, Karolinska University Hospital, Stockholm, Sweden.
Förderung
- National Natural Science Foundation of China
- Key Technologies Research and Development Program
- National Key Research and Development Program of China
- Zhejiang Province Natural Science Foundation
Zitieren
APA
Zhu, G., He, Y., Li, X., Xiao, Y., Zhan, H., Duan, M., & Guan, M. X. (2025). Mitochondrial tRNA processing defects reprogram mitochondrial and cellular homeostasis. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2025.110334
Vancouver
Zhu G, He Y, Li X, Xiao Y, Zhan H, Duan M, et al. Mitochondrial tRNA processing defects reprogram mitochondrial and cellular homeostasis. Journal of Biological Chemistry. 2025. doi:10.1016/j.jbc.2025.110334
BibTeX
@article{Zhu2025,
author = {Zhu, Gao and He, Yunfan and Li, Xincheng and Xiao, Yun and Zhan, Huisen and Duan, Maoli and Guan, Min-Xin},
title = {Mitochondrial tRNA processing defects reprogram mitochondrial and cellular homeostasis},
journal = {Journal of Biological Chemistry},
year = {2025},
doi = {10.1016/j.jbc.2025.110334}
}
EUVIMED